SG10201502642TA - Methods, Compounds, Compositions And Vehicles For Delivering 3-Amino-1-Propanesulfonic Acid - Google Patents

Methods, Compounds, Compositions And Vehicles For Delivering 3-Amino-1-Propanesulfonic Acid

Info

Publication number
SG10201502642TA
SG10201502642TA SG10201502642TA SG10201502642TA SG10201502642TA SG 10201502642T A SG10201502642T A SG 10201502642TA SG 10201502642T A SG10201502642T A SG 10201502642TA SG 10201502642T A SG10201502642T A SG 10201502642TA SG 10201502642T A SG10201502642T A SG 10201502642TA
Authority
SG
Singapore
Prior art keywords
delivering
vehicles
amino
compositions
compounds
Prior art date
Application number
SG10201502642TA
Other languages
English (en)
Inventor
Xianqi Kong
Mohamed Atfani
Benoit Bachand
Abderrahim Bouzide
Stephane Ciblat
Sophie Levesque
Isabelle Valade
Xinfu Wu
Daniel Delorme
David Migneault
Original Assignee
Bhi Ltd Partnership
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bhi Ltd Partnership filed Critical Bhi Ltd Partnership
Publication of SG10201502642TA publication Critical patent/SG10201502642TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/17—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing carboxyl groups bound to the carbon skeleton
    • C07C309/18—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing carboxyl groups bound to the carbon skeleton containing amino groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/38—Eight-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C07D317/40—Vinylene carbonate; Substituted vinylene carbonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • C07D323/02—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C07K5/06069—Ser-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P11/00—Preparation of sulfur-containing organic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/001—Amines; Imines
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201502642TA 2006-10-12 2007-10-12 Methods, Compounds, Compositions And Vehicles For Delivering 3-Amino-1-Propanesulfonic Acid SG10201502642TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85103906P 2006-10-12 2006-10-12
US91145907P 2007-04-12 2007-04-12

Publications (1)

Publication Number Publication Date
SG10201502642TA true SG10201502642TA (en) 2015-05-28

Family

ID=40341820

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011073327A SG175603A1 (en) 2006-10-12 2007-10-12 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
SG10201502642TA SG10201502642TA (en) 2006-10-12 2007-10-12 Methods, Compounds, Compositions And Vehicles For Delivering 3-Amino-1-Propanesulfonic Acid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2011073327A SG175603A1 (en) 2006-10-12 2007-10-12 Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Country Status (24)

Country Link
US (7) US8748656B2 (de)
EP (3) EP2089417B1 (de)
JP (4) JP5607930B2 (de)
KR (5) KR20170061720A (de)
CN (3) CN103787927B (de)
AU (1) AU2007357451B2 (de)
BR (1) BRPI0717794B8 (de)
CA (2) CA2666246C (de)
DK (2) DK2089417T3 (de)
EA (1) EA016568B1 (de)
ES (3) ES2891278T3 (de)
FI (1) FI3851447T3 (de)
HK (2) HK1133664A1 (de)
HU (2) HUE064514T2 (de)
IL (2) IL197852A (de)
LT (1) LT3851447T (de)
MX (1) MX339684B (de)
NZ (1) NZ576285A (de)
PL (2) PL2089417T3 (de)
PT (2) PT3851447T (de)
SG (2) SG175603A1 (de)
SI (2) SI2089417T1 (de)
WO (1) WO2009019534A2 (de)
ZA (1) ZA200903030B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
CA2666246C (en) 2006-10-12 2013-12-31 Bellus Health (International) Limited Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
EP2349988A4 (de) 2008-11-14 2012-05-02 Bellus Health Inc Organische nährsalze sowie verfahren zu ihrer herstellung und verwendung
WO2010096925A1 (en) * 2009-02-26 2010-09-02 Bellus Health (International) Limited Homotaurine-supplemented and/or enriched edible material, methods of preparation an d uses
WO2011153049A1 (en) * 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
WO2013192610A2 (en) 2012-06-23 2013-12-27 Fox Chase Chemical Diversity Center, Inc. Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
TW201418212A (zh) 2012-10-05 2014-05-16 Mitopharm Ltd 用於增進粒線體製造ａｔｐ之經保護的琥珀酸酯
WO2015143447A2 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
AU2015269198B2 (en) 2014-06-06 2020-12-10 The Scripps Research Institute Sulfur(VI) fluoride compounds and methods for the preparation thereof
US10525144B2 (en) * 2014-11-10 2020-01-07 The Johns Hopkins University Selective targeting of an anti-inflammatory receptor in human mitochondria and preservation of mitochondrial functions
MX2018001592A (es) 2015-08-10 2018-08-21 Alzheon Inc Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
CN105152986B (zh) * 2015-09-09 2017-08-25 武汉华纳联合药业有限公司 半胱氨酸‑高牛磺酸二肽及其衍生物及其医药用途
WO2017044840A1 (en) * 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population
US20180250249A1 (en) * 2016-02-02 2018-09-06 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular population
CA3053491A1 (en) * 2017-03-01 2018-09-07 Hdl Therapeutics, Inc. Methods for prophylactically preventing, slowing the progression of, or treating alzheimer's disease
WO2018174838A1 (en) * 2017-03-18 2018-09-27 Nguyen Mark Quang Cysteamine prodrugs, related analogs, pharmaceutical compositions thereof, and methods of use
CN108623501B (zh) * 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
EP3498283A1 (de) 2017-12-14 2019-06-19 Ipsol AG Glycosidische derivate von treprostinil
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
US11591301B2 (en) 2018-02-02 2023-02-28 Hinova Pharmaceuticals Inc. Indoleamine-2,3-dioxygenase inhibitor, preparation method therefor and use thereof
CN110668980A (zh) * 2018-07-03 2020-01-10 浙江京新药业股份有限公司 一种2-取代的高牛磺酸衍生物
SG11202100767XA (en) * 2018-08-01 2021-02-25 Alzheon Inc Methods for treating neurodegenerative disorders
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
CN112791078B (zh) * 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
WO2023212289A1 (en) 2022-04-28 2023-11-02 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases

Family Cites Families (261)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2319078A (en) 1940-06-13 1943-05-11 Eastman Kodak Co Aminophenol and its preparation
US2531468A (en) 1949-04-14 1950-11-28 Eastman Kodak Co Polyvinyl sulfonates and process for their preparation
DE927992C (de) 1952-07-27 1955-05-23 Hoechst Ag Verfahren zur Herstellung von Salzen des 1, 2-Dimethyl-3-phenyl-4-amino-5-pyrazolons
CH325458A (de) 1953-03-14 1957-11-15 Ruhrchemie Ag Verfahren zur Herstellung von Sultamen
BE543413A (de) 1953-09-19
DE1020144B (de) 1956-07-02 1957-11-28 Dehydag Gmbh Wasch- und Reinigungsmittel
US3230249A (en) 1959-07-01 1966-01-18 Monsanto Co Salts of (n-alkyl-n-sulfoalkylamino) alkyl alkylated phenols
DE1122064B (de) 1960-01-09 1962-01-18 Basf Ag Verfahren zur Einfuehrung von alyphatischen Kohlenwasserstoffresten in organische Verbindungen, die Hydroxylgruppen, tertiaere Aminogruppen, aromatische gebundene Sulfhydrylgruppen und bzw. oder aromatisch gebundene primaere oder sekundaere Aminogruppen enthalten
US3218352A (en) 1962-05-03 1965-11-16 Abbott Lab Homotaurine process
DE1192021B (de) * 1963-01-12 1965-04-29 Dehydag Gmbh Galvanische Baeder
US3351549A (en) 1964-06-19 1967-11-07 Universal Oil Prod Co Desalinization of aqueous solutions
US3622669A (en) 1967-10-23 1971-11-23 Merck & Co Inc 5{62 -taurocholenic acids and 5{62 -taurocholadienic acids in compositions for reducing the concentration of cholesterol and liads in blood serum
US3560936A (en) 1968-10-08 1971-02-02 Pillsbury Occidental Co Message buffering communication system
US3658966A (en) 1969-09-15 1972-04-25 Kowa Co Methods of treating hypertension
JPS4941186B1 (de) 1970-01-13 1974-11-07
DE2140278A1 (en) 1970-01-19 1972-03-09 Crompton and Knowles Corp., Worcester, Mass. (V.St.A.) Water-soluble dyes and dye intermediates
JPS494210Y1 (de) 1970-01-24 1974-01-31
DE2039993A1 (de) * 1970-08-12 1972-02-17 Basf Ag Optische Aufheller der Bisstyrylbenzolreihe
BE791595A (fr) * 1971-11-18 1973-05-17 Omf California Inc Electrolyte pour accumulateur
JPS514121Y2 (de) 1971-12-09 1976-02-05
US3872125A (en) 1973-03-03 1975-03-18 Sandoz Ag 3-substituted-4-aryl isoquinolines
US4085134A (en) 1974-02-15 1978-04-18 Petrolite Corporation Amino-phosphonic-sulfonic acids
IL47149A (en) 1974-04-29 1979-05-31 Chinoin Gyogyszer Es Vegyeszet Amino acid derivatives,their preparation and pharmaceutical compositions containing them
US3920833A (en) 1974-08-08 1975-11-18 Stanley Drug Products Inc Antifibrinolytic agents
FR2313923A1 (fr) 1975-06-13 1977-01-07 Lucien Laboratoires Nouvelle association douee notamment d'une activite analgesique, myorelaxante, anxiolytique et anti-inflammatoire
JPS5312812Y2 (de) 1975-09-26 1978-04-07
DE2547589A1 (de) 1975-10-24 1977-04-28 Agfa Gevaert Ag Haertung photographischer schichten
HU178199B (en) 1976-05-06 1982-03-28 Chinoin Gyogyszer Es Vegyeszet New process for producing amides of omega-amino-carboxylic acids
FR2384751A1 (fr) 1977-03-23 1978-10-20 Francaise Coop Pharma Nouveaux derives de la taurine a activite neuro-musculaire renforcee
US4197245A (en) 1977-12-08 1980-04-08 American Cyanamid Company 1-Hydroxymethyl-1-oxo-prostane derivatives of the A1 series
CA1144937A (en) 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
JPS54106560A (en) 1978-02-08 1979-08-21 Teijin Chem Ltd Flame-retardant polycarbonate resin composition
JPS5546706A (en) 1978-09-29 1980-04-02 Canon Inc Phase difference reflecting mirror
FR2437834A1 (fr) 1978-10-04 1980-04-30 Lejeune Jerome Compositions pharmaceutiques a base de l-serine ou de glycine
JPS577398Y2 (de) 1978-12-27 1982-02-12
FR2457281A1 (fr) 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
US4255448A (en) 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
JPS5921666Y2 (ja) 1981-03-31 1984-06-27 株式会社 益岡製作所 磯つり用のウキ止め
US4448779A (en) 1981-07-16 1984-05-15 Sanofi Use of MS salt in geriatric medicine
JPS5879022A (ja) 1981-11-04 1983-05-12 Bitamin Kenkyusho:Kk 第四級窒素原子を含有する新規な金属架橋高分子化合物、その製法及び該高分子化合物を有効成分とする高脂血症治療剤
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
FR2529546A1 (fr) 1982-07-05 1984-01-06 Meram Lab Nouveaux sels d'amino-(et imino-)acides a, o-sulfoniques n-substitues, vecteurs cationiques de haute penetration cellulaire
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4593045A (en) 1982-07-20 1986-06-03 Societe a Responsabilite Limite dite: B.F.B. Estudes et Recherches Experimentales N-acetyl-L-aspartyl taurine useful as hypertensive agent
FR2536747A1 (fr) 1982-11-29 1984-06-01 Synthelabo Derives benzylideniques soufres, leur preparation et leur application en therapeutique
IT1193590B (it) 1983-01-07 1988-07-08 Loris Jacopo Bononi Derivati amino-alchil-solfonici,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
JPS59108758U (ja) 1983-01-11 1984-07-21 株式会社リコー 複写紙整合装置
US4472392A (en) 1983-01-21 1984-09-18 The Upjohn Company Sulfonate containing ester prodrugs of corticosteroids
JPS59137500U (ja) 1983-03-07 1984-09-13 株式会社日本アルミ 水素の貯蔵装置
JPS6025937A (ja) 1983-07-22 1985-02-08 Mitsui Toatsu Chem Inc 有機スルホン酸又はその塩の製造方法
DE3343530A1 (de) 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
US4737353A (en) 1984-04-13 1988-04-12 Union Carbide Corporation Beryllium-aluminum-phosphorus-silicon-oxide molecular sieve compositions
DE3438291A1 (de) 1984-10-19 1986-04-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung einer waessrigen ueberzugsmitteldispersion und ihre verwendung zum ueberziehen von arzneimitteln
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
FR2584090B1 (fr) 1985-06-27 1987-08-28 Roussel Uclaf Nouveaux supports, leur preparation et les intermediaires obtenus, leur application a la synthese d'oligonucleotides et les nouveaux nucleosides et oligonucleotides relies aux supports ainsi obtenus
JPH0733332B2 (ja) 1985-11-19 1995-04-12 富山化学工業株式会社 痴呆症状改善・治療剤
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
FR2595356B1 (fr) 1986-03-05 1991-05-24 Pasteur Strasbourg Universite Derives des nitro ou aminobenzyltetrahydroisoquinoleines, procedes d'obtention, compositions pharmaceutiques les contenant, proprietes pharmacologiques et applications
JPH0786122B2 (ja) 1986-05-30 1995-09-20 日本ペイント株式会社 三次元架橋された微小樹脂粒子およびその製造法
GB2193206B (en) * 1986-07-31 1990-02-14 Farmitali Carlo Erba S P A Preparation of taurine-containing peptides
US4919915A (en) 1987-03-03 1990-04-24 Paul Averback Method for detecting the ability to prevent red-to-green congophilic birefringence
US5039794A (en) 1986-09-19 1991-08-13 Otsuka Pharmaceutical Co., Ltd. Tumor egress factor and processes for producing the same
US4847082A (en) 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
AU1790988A (en) 1987-05-19 1988-12-21 Baylor College Of Medicine Phosphoethanolamine for treatment of alzheimer's disease
IT1205042B (it) 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
IT1211792B (it) 1987-09-21 1989-11-03 Sigma Tau Ind Farmaceuti O-alcanoil derivati dell'acido 3ammino-2-idrossipropansolfonico adattivita'anticonvulsivante e loro composizioni farmaceutiche per il trattamento terapeutico dell'epilessia
WO1989004671A1 (en) 1987-11-18 1989-06-01 State Of Oregon Acting By And Through The State Bo Differential delivery of therapeutic agents across the blood brain barrier
JPH01171638A (ja) 1987-12-25 1989-07-06 Kanegafuchi Chem Ind Co Ltd 血清アミロイドａ蛋白用吸着体
JP2587842B2 (ja) 1987-12-09 1997-03-05 株式会社ニチレイ 神経疾患治療・予防剤
DK505488D0 (da) 1987-12-21 1988-09-09 Bar Shalom Daniel Middel og anvendelse af samme
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4968678A (en) 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
ATE87918T1 (de) 1988-02-19 1993-04-15 Lilly Co Eli Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
US5284876A (en) 1988-02-26 1994-02-08 Neuromedica, Inc. Method of treating tardive dyskinesia using dopaminergic agents of prodrugs of therapeutic agents
WO1989011299A1 (en) 1988-05-18 1989-11-30 State Of Oregon Acting By And Through The State Bo Method for delivery of therapeutic agents to target brain tissue using monoclonal antibody conjugates
JPH0627072B2 (ja) 1988-09-13 1994-04-13 呉羽化学工業株式会社 アミノ安息香酸誘導体を有効成分とする生体内抗酸化機構調節剤
JPH0667472B2 (ja) 1988-11-28 1994-08-31 鐘淵化学工業株式会社 血清アミロイドｐ蛋白用吸着体
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
JP2761048B2 (ja) 1989-08-25 1998-06-04 三共株式会社 神経成長因子産生促進剤
DK437289D0 (da) 1989-09-04 1989-09-04 Hans Bundgaard Prodrug derivatives of thyrotropin-releasing hormone (trh)
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
CA2067183A1 (en) 1989-09-27 1991-03-28 Lee L. Rubin Compositions for cell adhesion inhibition and methods of use
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
DE3940410A1 (de) 1989-12-04 1991-06-06 Schering Ag Neue verwendung von nmda-rezeptor-antagonisten
JPH03236315A (ja) 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
DE4004978A1 (de) 1990-02-19 1991-08-22 Nmi Naturwissenschaftl U Mediz Praeventive therapie fuer morbus alzheimer
DE69127749T2 (de) 1990-03-20 1998-04-16 Univ Columbia Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
US5091432A (en) 1990-03-28 1992-02-25 Glasky Alvin J 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5242932A (en) 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
ES2217250T3 (es) 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
DE4021066A1 (de) 1990-07-03 1992-01-09 Hoechst Ag Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
JP3070687B2 (ja) 1990-07-19 2000-07-31 日本臓器製薬株式会社 心疾患治療剤
DE69125216T2 (de) 1990-07-19 1997-09-25 Nippon Zoki Pharmaceutical Co Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
JP3068841B2 (ja) 1990-08-23 2000-07-24 日本臓器製薬株式会社 アミノアルカンスルホン酸誘導体を有効成分として含有する心疾患治療剤
US5137873A (en) 1990-07-27 1992-08-11 The Children's Medical Center Corporation Substance p and tachykinin agonists for treatment of alzheimer's disease
JP2858925B2 (ja) 1990-10-19 1999-02-17 株式会社クラレ 耐熱水性ポリビニルアルコール系繊維の製造法
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5270312A (en) 1990-11-05 1993-12-14 Warner-Lambert Company Substituted piperazines as central nervous system agents
JP2980749B2 (ja) 1990-11-30 1999-11-22 協和醗酵工業株式会社 フラン誘導体
ES2236682T5 (es) 1991-01-21 2011-03-31 Elan Pharmaceuticals, Inc. Ensayo y modelo para la enfermedad de alzheimer.
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
CA2104594C (en) 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
US5164295A (en) 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5192753A (en) 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
GB9117716D0 (en) 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5705401A (en) 1991-11-12 1998-01-06 The University Of Melbourne Method of assaying for alzheimer's disease
JPH06184069A (ja) 1991-11-19 1994-07-05 Lonza Ag α−ヒドロキシ−β−アミノカルボン酸の製造方法
EP0545198B1 (de) 1991-11-29 1999-09-15 Hoechst Aktiengesellschaft Peptide mit insulinartiger Wirkung
ATE147404T1 (de) 1991-12-19 1997-01-15 Ciba Geigy Ag Aminosulfonsäurederivate und verfahren zu ihrer herstellung
ES2204899T3 (es) 1992-01-07 2004-05-01 Elan Pharmaceuticals, Inc. Modelos de animales transgenicos para la enfermedad de alzheimer.
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
JP3390873B2 (ja) 1992-05-14 2003-03-31 株式会社常光 血清蛋白分画のｍ蛋白検出方法
US5318958A (en) 1992-05-29 1994-06-07 Queen's University At Kingston Amyloid precursor protein
EP0642337B1 (de) 1992-05-29 1997-09-03 University Of British Columbia Dapsone und promin zur behandlung der demenz
US5258402A (en) 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
EP0604641B1 (de) 1992-06-30 2002-03-20 SHAPIRO, Howard, K. Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
RU2157239C2 (ru) 1992-07-13 2000-10-10 Юкэрион, Инк. Способ модификации, способ обеспечения связывания белка с антителом, фармацевтические композиции, способ диагностики
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
EP0614886B1 (de) 1992-07-30 1996-10-16 Drug Delivery System Institute, Ltd. Im intracerebralen bereich verweisende verbindungen und deren anwendung
US5264219A (en) 1992-08-07 1993-11-23 Minnesota Mining And Manufacturing Company Transdermal drug delivery backing
US5383988A (en) 1992-09-10 1995-01-24 Paragon Trade Brands, Inc. Modular apparatus for fabricating an absorbent article
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
JPH06138110A (ja) 1992-10-27 1994-05-20 Takatoshi Hattori イオンクロマトグラフィー用分離カラム
EP0599303A3 (de) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide-Konjugate
IL107950A (en) * 1992-12-15 2001-04-30 Upjohn Co b 7, b 8 - Matano - Taxols, their preparation and pharmaceutical preparations against malignant tumors containing them
JP3164673B2 (ja) * 1992-12-16 2001-05-08 花王株式会社 新規糖アミノスルホン酸化合物及びその製造法並びにそれを含有する界面活性剤組成物
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
EP1060750B1 (de) 1993-03-29 2005-12-07 Queen's University At Kingston Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable Salze zur Behandlung von Amyloidosis
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5972328A (en) 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
DE4313118A1 (de) 1993-04-22 1994-10-27 Hoechst Ag Verwendung von 1,2,3,4-Tetrahydroisochinolin-Derivaten als Antimykotika
US5434137A (en) 1993-05-10 1995-07-18 Black; Keith L. Method for selective opening of abnormal brain tissue capillaries
AU6836394A (en) 1993-06-01 1994-12-20 Cortex Pharmaceuticals, Inc. Use of metabotropic receptor agonists in progressive neurodegenerative deseases
AU7642494A (en) 1993-08-31 1995-03-22 Gliatech Inc. Inhibition of beta amyloid binding to glycosaminoglycans for treatment of alzheimer's disease
WO1995007092A1 (en) 1993-09-10 1995-03-16 The University Of Medicine And Dentistry Of New Jersey Blood-brain barrier transporters of neurological agents
ATE198622T1 (de) 1993-10-27 2001-01-15 Elan Pharm Inc Transgene tiere, die app allele mit der schwedischen mutation beherbergen
US5488145A (en) 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5776970A (en) * 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
EP0952841A4 (de) 1994-08-05 2000-11-02 Molecular Structural Biotechno Biomolekulare komplexe für gerichteten transport von arzneimitteln in spezielle regionen
EP0778773A1 (de) 1994-08-08 1997-06-18 Albert Einstein College Of Medicine Of Yeshiva University Verfahren zur behandlung und/oder vorbeugung von alzheimer'sche krankheit mit phenothiazine und/oder thioxanthene
US5466683A (en) 1994-08-25 1995-11-14 Teva Pharmaceutical Industries Ltd. Water-soluble analogs of carbamazepine
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
JPH11502509A (ja) 1995-01-16 1999-03-02 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション 治療用化合物 − 脂肪酸抱合体
US5976822A (en) 1995-05-18 1999-11-02 Coulter International Corp. Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
US6015555A (en) 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US6187991B1 (en) 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
US5858326A (en) 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
CA2242851A1 (en) 1995-08-17 1997-02-27 The Ontario Cancer Institute Protein fibril assembly assay
DE19531342B4 (de) 1995-08-25 2007-11-29 Merz Pharma Gmbh & Co. Kgaa Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren
AU6887996A (en) 1995-09-01 1997-04-01 Washington University School Of Medicine Method of reducing neurotoxic injury with zinc chelators
AU6959896A (en) 1995-09-01 1997-03-27 Howard K. Shapiro Methods and compositions for development of drug screening procedures and diagnostic tools
WO1997014306A1 (en) 1995-10-17 1997-04-24 Dovetail Technologies, Inc. Low molecular weight cell, bone marrow and immune stimulants
JPH09178755A (ja) 1995-10-27 1997-07-11 Kyowa Medex Co Ltd ビリルビンの定量方法及び定量試薬
US5972956A (en) 1995-11-02 1999-10-26 Warner-Lambert Company Inhibition of amyloidosis by 9-acridinones
AU703540B2 (en) 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
US6043283A (en) 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
JP2002514184A (ja) 1996-09-27 2002-05-14 ギルフォード ファーマスーティカルズ インコーポレイテッド Ｎａａｌａｄアーゼ組成物ならびに動物におけるグルタメート異常を治療する方法および神経活性をもたらす方法
US5989592A (en) 1996-10-03 1999-11-23 Coastside Bio Resources Inhibition of complement pathway by sea cucumber fractions
SE9604582D0 (sv) 1996-12-13 1996-12-13 Astra Ab Novel compounds
JPH10204476A (ja) 1997-01-17 1998-08-04 Kanebo Ltd 界面活性剤
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US6057373A (en) 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
EP1001987B1 (de) 1997-08-01 2010-12-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein-aggregaten
US5869469A (en) 1997-08-18 1999-02-09 Queen's University At Kingston Phosphonocarboxylate compounds for treating amyloidosis
NZ550116A (en) 1997-08-18 2008-03-28 Neurochem Int Ltd Phosphono-carboxylate compounds for treating amyloidosis
JP4659209B2 (ja) 1997-08-28 2011-03-30 ユニバーシティ・オブ・ワシントン アルツハイマー病および他のアミロイド症を治療するための特定の糖組成物
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
EP1047436B1 (de) 1998-01-13 2009-10-21 Synchroneuron, LLC N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
ATE251129T1 (de) * 1998-01-27 2003-10-15 Merck Sante Sas Derivatives of aminoalkane sulphonic, phosphonic and phosphinic acids, their preparation and their use as medicaments
JP2002501887A (ja) 1998-01-28 2002-01-22 ワーナー−ランバート・カンパニー アルツハイマー病の治療方法
CA2320224C (en) 1998-02-11 2008-08-12 Neurochem, Inc. Method for modulating macrophage activation
US20020022657A1 (en) 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
AU2689699A (en) 1998-02-24 1999-09-06 Dovetail Technologies, Inc. Small molecules that increase the conversion of food to body weight gain
US6329356B1 (en) 1998-04-10 2001-12-11 Neurochem, Inc. Phosphono-carboxylate compounds for treating amyloidosis
JP2002515429A (ja) 1998-05-15 2002-05-28 ネウロケム、インク ニューロン細胞死を調節する方法
US7220427B2 (en) 1998-07-08 2007-05-22 Oryxe Mixture for transdermal delivery of low and high molecular weight compounds
US6310073B1 (en) 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US20030044776A1 (en) 1998-09-25 2003-03-06 James A. Dykens Compositions and methods for identifying agents that alter mitochondrial permeability transition pores
WO2000057707A1 (en) 1999-03-15 2000-10-05 Proteotech, Inc. Methods of treating alzheimer's disease and other amyloidoses using hypericum perforatum and derivatives thereof
WO2000056328A1 (en) 1999-03-19 2000-09-28 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
DE60042896D1 (de) 1999-04-28 2009-10-15 Bellus Health Int Ltd Zusammensetzungen und verfahren zur behandlung von amyloidosis mit sulphonatderivaten
WO2000068263A2 (en) 1999-05-05 2000-11-16 Neurochem, Inc. Stereoselective antifibrillogenic peptides and peptidomimetics thereof
GB9911095D0 (en) 1999-05-13 1999-07-14 Secr Defence Microbiological test method and reagents
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
EP1237547A2 (de) 1999-07-09 2002-09-11 Isis Innovation Limited Verbindungen zur krankheitshemmung und zur bereitung von zellen zur transplantation
US6489291B1 (en) 1999-10-05 2002-12-03 Kao Corporation Topical composition for skin
US6297226B1 (en) 1999-10-15 2001-10-02 Neotherapeutics, Inc. Synthesis and methods of use of 9-substituted guanine derivatives
US6455589B1 (en) 1999-10-28 2002-09-24 The Regents Of The University Of California Primary N-hydroxylamines
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
WO2001039796A2 (en) * 1999-11-29 2001-06-07 Neurochem Inc. Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US20050074487A1 (en) 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
KR20090016517A (ko) 1999-12-23 2009-02-13 벨루스 헬스 (인터내셔널) 리미티드 대뇌 아밀로이드 혈관병증을 조절하는 화합물 및 방법
WO2001052903A1 (en) 2000-01-19 2001-07-26 Genteric, Inc. Method for nucleic acid transfection of cells
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
US6376557B1 (en) 2000-03-16 2002-04-23 Chanda Bhuwalka Zaveri Methods for treating alopecia
KR100799192B1 (ko) * 2000-07-19 2008-01-31 미쯔비시 웰 파마 가부시키가이샤 히드록삼산계 설폰산 유도체 및 그의 의약 용도
US20020115717A1 (en) 2000-07-25 2002-08-22 Francine Gervais Amyloid targeting imaging agents and uses thereof
US7311893B2 (en) 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
IL157845A0 (en) 2001-03-13 2004-03-28 Univ Kingston Anti-epileptogenic agents
US20020182600A1 (en) 2001-04-11 2002-12-05 Smith Jack V. Method for assaying biological and other constituents using synthetic nucleounits in lateral flow, liquid, and dry chemistry techniques
US7501429B2 (en) 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
US6759427B2 (en) 2001-04-20 2004-07-06 Spectrum Pharmaceuticals, Inc. Synthesis and methods of use of tetrahydroindolone analogues and derivatives
CA2448160A1 (en) 2001-05-25 2002-12-05 Queen's University At Kingston Heterocyclic beta-amino acids and their use as anti-epileptogenic agents
US7514098B2 (en) 2001-05-30 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Use of targeted cross-linked nanoparticles for in vivo gene delivery
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
IL160208A0 (en) 2001-08-31 2004-07-25 Neurochem Int Ltd Amidine derivatives for treating amyloidosis
US20030077833A1 (en) 2001-09-07 2003-04-24 Queen's University At Kingston Diagnositc methods for determining susceptibility to convulsive conditions
EP1298125A1 (de) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituierte Benzimidazolverbindungen und ihre Verwendung zur Behandlung von Krebs
WO2003053337A2 (en) * 2001-11-09 2003-07-03 Advanced Therapeutics & Diagnostics, Lc Therapeutic compositions
NZ537360A (en) 2002-06-25 2006-09-29 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20060135403A1 (en) * 2002-12-24 2006-06-22 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
EP1601649A4 (de) * 2003-02-19 2009-03-04 Endacea Inc A1-adenosinrezeptorantagonisten
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20050215562A1 (en) 2003-06-23 2005-09-29 Patrick Tremblay Methods for treating protein aggregation disorders
AU2004251717B2 (en) 2003-06-23 2010-03-11 Bellus Health (International) Limited Treatment of amyloid- and epileptogenesis-associated diseases
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050038000A1 (en) 2003-06-23 2005-02-17 Xianqi Kong Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
CA2529269C (en) * 2003-06-23 2012-02-07 Neurochem (International) Limited Improved pharmaceutical drug candidates and methods for preparation thereof
BRPI0411743A (pt) * 2003-06-23 2006-08-08 Neurochem Int Ltd método e composições para tratar doenças relacionadas a amilóides
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7253306B2 (en) 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
CN100528840C (zh) * 2003-06-23 2009-08-19 贝卢斯健康(国际）有限公司 改进的候选药物及其制备方法
KR101139314B1 (ko) 2003-08-29 2012-04-26 베르날리스(캠브리지)리미티드 피리미도티오펜 화합물
JP2005200314A (ja) 2004-01-13 2005-07-28 Mitsubishi Pharma Corp ヒドロキサム酸系スルホン酸誘導体の製造方法
FR2865205B1 (fr) 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
US7262223B2 (en) 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
CA2508585A1 (en) 2004-06-01 2005-12-01 Axonyx, Inc. Transdermal delivery system for treatment of cognitive disorders
EP1841460A2 (de) 2004-06-18 2007-10-10 Neurochem (International) Limited Therapeutische formulierungen zur behandlung von beta-amyloid-bedingten erkrankungen
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
WO2006050471A2 (en) 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US20060183800A1 (en) 2004-11-12 2006-08-17 Xianqi Kong Methods and fluorinated compositions for treating amyloid-related diseases
US20060167057A1 (en) 2004-11-16 2006-07-27 Xianqi Kong Compounds for the treatment of CNS and amyloid associated diseases
CA2592320C (en) * 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20060251714A1 (en) 2005-04-12 2006-11-09 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
JP4951752B2 (ja) 2005-11-17 2012-06-13 国立大学法人高知大学 易動度の正規化装置、正規化方法、正規化プログラムおよび自己組織化マップ、並びに、物質の検出方法、検出プログラム、検出ルール生成方法およびデータ構造
CA2666246C (en) 2006-10-12 2013-12-31 Bellus Health (International) Limited Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
JP5312812B2 (ja) 2008-01-23 2013-10-09 株式会社Ａｄｅｋａ セルロース系樹脂組成物およびセルロース系樹脂フィルム

Also Published As

Publication number Publication date
KR101547612B1 (ko) 2015-08-27
CN101600730B (zh) 2014-01-29
US20200253897A1 (en) 2020-08-13
PT2089417E (pt) 2015-04-14
KR101608445B1 (ko) 2016-04-01
CN103787927A (zh) 2014-05-14
US11020360B2 (en) 2021-06-01
PL2089417T3 (pl) 2015-07-31
CN101600730A (zh) 2009-12-09
SI2089417T1 (sl) 2015-04-30
EP2862581A3 (de) 2015-08-12
MX2009003768A (es) 2009-09-28
ES2533463T3 (es) 2015-04-10
EP3851447B1 (de) 2023-09-06
WO2009019534A2 (en) 2009-02-12
KR101443573B1 (ko) 2014-11-03
CA2666246C (en) 2013-12-31
KR20090080054A (ko) 2009-07-23
JP5607930B2 (ja) 2014-10-15
IL240454A0 (en) 2015-09-24
ES2967330T3 (es) 2024-04-29
JP2019023197A (ja) 2019-02-14
NZ576285A (en) 2012-02-24
US10857109B2 (en) 2020-12-08
KR101742179B1 (ko) 2017-05-31
CA2666246A1 (en) 2009-02-12
HK1209628A1 (en) 2016-04-08
IL197852A0 (en) 2011-08-01
MX339684B (es) 2016-06-06
JP2015007047A (ja) 2015-01-15
LT3851447T (lt) 2023-12-27
HK1133664A1 (en) 2010-04-01
DK3851447T3 (da) 2023-12-04
KR20150001812A (ko) 2015-01-06
CN106946748A (zh) 2017-07-14
EP3851447A1 (de) 2021-07-21
BRPI0717794A2 (pt) 2013-10-29
US20170095430A1 (en) 2017-04-06
DK2089417T3 (en) 2015-03-23
EP2089417B1 (de) 2014-12-31
US20140220122A1 (en) 2014-08-07
JP6659792B2 (ja) 2020-03-04
US20240065990A1 (en) 2024-02-29
PL3851447T3 (pl) 2024-03-04
ES2891278T3 (es) 2022-01-26
US8748656B2 (en) 2014-06-10
BRPI0717794B8 (pt) 2021-05-25
PT3851447T (pt) 2023-12-11
JP2010514674A (ja) 2010-05-06
IL240454B (en) 2019-10-31
EA016568B1 (ru) 2012-05-30
SI3851447T1 (sl) 2024-02-29
AU2007357451B2 (en) 2012-11-15
EA200970287A1 (ru) 2009-12-30
HUE064514T2 (hu) 2024-03-28
ZA200903030B (en) 2010-11-24
IL197852A (en) 2015-08-31
US20210386693A1 (en) 2021-12-16
EP2862581A2 (de) 2015-04-22
KR20170061720A (ko) 2017-06-05
HUE024950T2 (en) 2016-02-29
CN103787927B (zh) 2017-03-01
US20200009086A1 (en) 2020-01-09
WO2009019534A3 (en) 2009-08-13
AU2007357451A1 (en) 2009-02-12
JP6013403B2 (ja) 2016-10-25
BRPI0717794B1 (pt) 2019-08-06
KR20160039309A (ko) 2016-04-08
EP2089417A2 (de) 2009-08-19
US20080146642A1 (en) 2008-06-19
JP2016222671A (ja) 2016-12-28
CA2830727C (en) 2016-11-29
FI3851447T3 (fi) 2023-11-15
KR20140084050A (ko) 2014-07-04
SG175603A1 (en) 2011-11-28
US10238611B2 (en) 2019-03-26
CA2830727A1 (en) 2009-02-12
EP2862581B1 (de) 2021-08-11
US9499480B2 (en) 2016-11-22
CN106946748B (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
HK1209628A1 (en) Methods, compounds, compositions and vehicles for delivering 3-amino- 1-propanesulfonic acid 3--1-
EP2464626A4 (de) Verfahren, verbindungen und zusammensetzungen zur ausgabe von 1,3-propandisulfonsäure
EP2006146A4 (de) Antriebssatz für fahrzeuge
EP2064045A4 (de) Kunststoffakzeptorhybridkomponenten
EP2095979A4 (de) Fahrzeugsteuerung
HK1134029A1 (en) Amino acid composition
EP2094118A4 (de) Verbesserte peressigsäure-zusammensetzung
EP2070740A4 (de) Fahrzeugsteuerung
EP2282735A4 (de) Verbindungen, zusammensetzungen und verfahren zu ihrer herstellung
GB0603160D0 (en) Nucleic acid
ZA200901702B (en) Self-preserved aqueous pharmaceutical compositions
HK1131402A1 (en) Polylactic acid composition
KR100496606B1 (en) Composition for anti-cancer comprising poly- -glutamic acid
GB0616575D0 (en) Additive system
EP2034019A4 (de) Zusammensetzung zur nukleinsäureeinführung
GB0602780D0 (en) Amino Acid Derivatives
EP2072498A4 (de) N-phenyloxamidinsäurederivat
IL205644A0 (en) Methods for administering corticosteroid formulations
PT1849360E (pt) Novo uso para ácido 2-hidroxi-4-metiltiobutanóico (hmtb)
HK1151801A1 (en) 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid
EP2128136A4 (de) 2-phenylnicotinsäurederivat
EP2216410A4 (de) Verfahren zur herstellung von -aminosäure
IL184372A0 (en) Method for delivering interferon-??
AU3541P (en) OB1 Vaccinium hybrid
HUP0600795A2 (en) Small trailer for cars